SAMHSA Just Made It Cheaper to Die Than to Know What You're Dying From

In the first three months of this year, the Kentucky Harm Reduction Coalition handed out 48,465 fentanyl test strips — small paper strips that tell someone, in about two minutes, whether the powder or pill they’re about to use contains fentanyl before it’s in their body instead of after. That’s what Kentucky Harm Reduction Coalition actually did in Q1 of fiscal year 2026, in a state posting its fourth straight year of falling overdose deaths. On April 25, executive director Shreeta Waldon learned the $400,000 federal grant funding that work was gone. She has about a month of test strips left before the supply runs out.

“It doesn’t make sense that one day something is an evidence-based protocol,” Waldon told CBS News, “and you decide, because of political climate, it is no longer evidence-based.”

She’s not being rhetorical. It was evidence-based on April 23. On April 24, 2026, SAMHSA — the federal agency funding most of the country’s addiction infrastructure — sent grantees a Dear Colleague letter banning federal dollars for fentanyl, xylazine, and medetomidine test strips, plus sterile syringes, overdose hotlines, and pipes.

SAMHSA just made it cheaper to die than to know what you’re dying from.

A fentanyl test strip costs roughly a dollar. The thing it detects now shares the drug supply with something that can kill you in a way naloxone — the opioid-overdose reversal medication that restarts someone’s breathing — cannot touch. The timing isn’t just bad. It’s the kind of coincidence that, if you tried to design the worst possible month to defund drug-checking, you couldn’t engineer something more precise.

A’zhane Powell, who runs Fyrebird Recovery in South Carolina and lost a $4,000 grant in the same sweep, asked the question underneath all of this: “How far will it go until we’re back to square one again?”

Medetomidine took over Philadelphia’s dope supply in the same window SAMHSA decided testing for it doesn’t deserve federal money

Here’s the plain-language version first, because this drug did not exist in most people’s vocabulary two years ago. Medetomidine is a veterinary sedative — it’s what vets use to knock out large animals for procedures — and it belongs to a drug class called alpha-2 agonists, which just means it works by calming down your nervous system’s “fight or flight” signal rather than by hitting opioid receptors the way fentanyl or heroin do. Because it doesn’t touch opioid receptors, naloxone doesn’t reverse it. Naloxone will restart someone’s breathing if fentanyl is what’s stopping it, but a person can still be unconscious and unresponsive afterward, sedated by the medetomidine sitting alongside it, and there is currently no approved medication that reverses that sedation in the field. That’s the whole crisis in one sentence: the tool that has saved more lives than anything else in the overdose response — naloxone — doesn’t work on the thing that’s replacing what it used to work on.

Medetomidine is chemically related to dexmedetomidine, a sedative used in ICUs, and according to an editorial in American Family Physician by Dr. Judy Chertok and Dr. Navid Roder of the University of Pennsylvania Health System, it’s up to 300 times more potent than xylazine — the last veterinary sedative to invade the opioid supply, and the one most harm reduction workers had only just finished building protocols around. Xylazine, sometimes called “tranq,” causes severe skin wounds and was itself only added to federal test-strip funding eligibility a few years ago after a hard-fought advocacy push. Medetomidine didn’t wait for anyone to catch up. It just took the market — one of several novel and emerging substances now reshaping what “the supply” even means from one season to the next.

The numbers are not subtle. According to Substance Use Philly, the city health department’s own drug-checking program, medetomidine went from 29% of tested “dope” samples in May 2024 to 90% in March 2026 — while xylazine, which had been in 97% of samples, fell to 28% over the same stretch. That’s not a slow drift. That’s a near-total replacement of one adulterant with a more dangerous one, tracked in real time, in a city with one of the country’s most sophisticated drug-checking operations. The same program states it plainly: “Medetomidine is not an opioid, so naloxone (NARCAN®) will not reverse a purely medetomidine overdose.” Someone can get naloxone, start breathing again, and still be unrousable on a sidewalk for hours. First responders are now told to watch breathing, not consciousness, because consciousness may not come back on the timeline anyone’s used to.

First responders are now told to watch breathing, not consciousness, because consciousness may not come back on the timeline anyone’s used to.

This is exactly the kind of shift a test strip is built to catch — assuming it’s legal to hand one out. If you’ve ever dipped a strip before you used, you already know what that dollar buys you: two minutes and a piece of information nobody else in that moment is going to give you for free. You know what it means when the strip that used to just flag fentanyl might now be the only warning you get that something is in there your naloxone can’t fix. And as of April 24, 2026, the federal government decided that information is no longer worth funding.

This isn’t isolated to Philadelphia or to medetomidine. STAT News reported in June that nitazenes — synthetic opioids the DEA’s Frank Tarentino calls “shape shifters,” some up to 40 times stronger than fentanyl — have spread to 48 of 50 states, with confirmed positive tests rising from 43 in 2019 to nearly 2,000 in 2024. Dealers adapt to regulation faster than regulation adapts to them, and every time the supply mutates, the tools that let a person check what they’re about to use become more valuable, not less. SAMHSA moved in the opposite direction at the exact moment the ground shifted under it.

The government has run this experiment before, and we already know the death toll it produces

In 1988, with the HIV epidemic tearing through communities of people who injected drugs, Congress banned federal funds for syringe exchange programs — at the time, the single intervention doing the most to slow HIV transmission among people who inject drugs. Lawmakers said funding clean syringes would “send the wrong message” about drug use. It didn’t matter that the public health case was settled, or that people were dying of a preventable, bloodborne disease. The ban held for 21 years, through the peak of the era’s AIDS crisis, until it was lifted in 2009. Researchers have since gone back and counted the infections that accumulated in between. The “wrong message” framing was never a policy argument. It was a choice to prioritize how a program looked over what it did — paid for in bodies.

That’s the through-line here, and it’s not subtle: a government looked at a cheap, evidence-backed tool that kept people who use drugs alive, decided it sent the wrong message, and pulled the funding — then took decades to admit what that cost. We are not speculating that this will happen again. We are watching the opening moves of the same decision, with a different tool and a more lethal drug supply, and pretending it’s a novel policy debate insults everyone who lived through the first one.

ASHP and Kentucky’s own numbers show this wasn’t a funding gap — it was a reversal of settled evidence

The American Society of Health-System Pharmacists doesn’t often issue statements opposing federal drug policy. It did here. In an April 30, 2026 statement, ASHP said it opposes SAMHSA’s decision to end federal funding for fentanyl, xylazine, and medetomidine test strips distributed for individual use, citing multiple studies showing test strips reduce overdose deaths. Tom Kraus, ASHP’s vice president of government relations, put the pharmacist’s stake in it directly: “Pharmacists should not be prevented from providing access to harm-reduction tools that reduce the risk of overdose.” ASHP’s concern isn’t abstract — pharmacists are often the last trusted, accessible point of contact a person who uses drugs has with the health system, and test strips have increasingly moved through that channel specifically because it works.

The American Society of Addiction Medicine responded with more caution but the same underlying discomfort. ASAM president Dr. Stephen Taylor said the organization was “continuing to carefully review the new Dear Colleague letters from SAMHSA and is prepared to engage with federal partners to ensure that national policies reflect evidence-based practices in addiction medicine.” Translation, from a group not known for picking fights: this doesn’t look like evidence-based practice, and we’re going to say so through the proper channels before this goes further.

The American Society of Addiction Medicine responded with more caution but the same underlying discomfort.

What makes Kentucky’s case so hard to wave away is that it’s not a hypothetical about programs enabling drug use — it’s a state posting real outcomes in the opposite direction. Kentucky logged a 22.9% decline in overdose deaths in 2025, its fourth consecutive year of falling mortality, built substantially on naloxone saturation and exactly the kind of harm reduction expansion — including test-strip distribution — that just lost its funding. Waldon’s coalition didn’t hand out 48,465 strips because federal auditors weren’t watching. They handed them out because the state’s own numbers said it was working, on a program SAMHSA’s own July 2025 letter had listed as supported before April’s letter reversed course entirely.

Multiply Kentucky’s story by every state and tribal grantee who built a program around the assumption that test strips, syringes, and overdose hotlines — phone lines someone can call while using, so another person is listening if something goes wrong, which SAMHSA now frames as facilitating drug use rather than preventing death — were durable, fundable public health tools, not politically contingent ones. STAT News reported SAMHSA’s own headcount has been cut from roughly 900 employees to less than half that, alongside roughly $1.7 billion in cancelled block grants and another $350 million cut from addiction and overdose prevention funding specifically. Test strips are just the most legible casualty, because you can count them one at a time — 48,465 in a single quarter, in a single state.

The overdose decline everyone’s citing as vindication is the same decline this policy threatens to reverse

Here’s the argument SAMHSA and its defenders would make, if pressed: overdose deaths are falling, so whatever we’re doing is working, and harm reduction tools aren’t the thing holding the line. The data says otherwise, and it says so specifically enough to name. CDC provisional data released in May 2026 shows 69,973 overdose deaths for the 12-month period ending in the reporting window, down from 81,313 the year before — a decline of nearly 14%, the third consecutive year of falling numbers nationally. Opioid-involved deaths specifically dropped from an estimated 55,296 to 44,564. This is real, it’s significant, and it did not happen by accident.

It happened during the exact years that fentanyl test strip distribution, naloxone saturation, and syringe service programs scaled up nationally after over a decade of advocacy to make them federally fundable at all. Public health researchers point to naloxone access, drug-checking, and treatment expansion as the most credible drivers of the decline — not a single cause, but a stack of interventions that includes, unambiguously, the exact tools this policy now defunds. You don’t get to credit the trend line for your approach while pulling the specific interventions that bent it. Either the tools mattered, in which case cutting them risks the trend, or they didn’t, in which case SAMHSA owes the public an explanation for why it funded fentanyl test strips at all for the past several years. Both can’t be true, and the agency hasn’t tried to reconcile them.

Geography makes the stakes concrete. The CDC data shows steep declines — over 25% — in states like Rhode Island, New York, North Carolina, and Vermont, states with mature harm reduction infrastructure. Meanwhile New Mexico, Arizona, and Colorado saw increases of 10% or more. That spread isn’t proof of causation on its own, but it’s exactly the kind of variation you’d want to study before deciding, nationally, that the interventions built into the successful states don’t deserve federal money anymore. Nobody at SAMHSA appears to have run that comparison before writing the April 24 letter.

What’s still standing, and what to do with that tonight

Naloxone funding has not been touched by this policy. That’s not a footnote — say it plainly, because it’s the one piece of true information in all of this that a person should walk away holding onto tonight. If you have naloxone, or you can get it from a local health department, syringe service program, or pharmacy, that access hasn’t changed. What has changed is your ability to know, in advance, whether what you’re about to use contains something naloxone won’t touch. That gap — between what still works and what you can no longer find out — is the actual shape of this policy, and it’s worth being precise about which side of that line you’re standing on before you use.

What has changed is your ability to know, in advance, whether what you’re about to use contains something naloxone won’t touch.

The people fighting this aren’t waiting for federal permission to keep working. Harm reduction organizations across the country are looking for state funding, private philanthropy, and pharmacy-based distribution channels — the same channel ASHP is defending — to keep test strips moving while the federal door is closed. Kentucky Harm Reduction Coalition is still operating. Fyrebird Recovery is still operating. The Rize Recovery newsroom’s harm reduction coverage will keep tracking where those replacement dollars come from, and whether they arrive before Waldon’s month of strips runs out.

In 1988, someone in a position of federal authority decided that a piece of paper telling people the truth about what was in their blood supply sent the wrong message, and 21 years passed before that decision was reversed. It is 2026. The paper this time is a test strip instead of a syringe, and the drug is medetomidine instead of HIV, but the logic hasn’t changed at all: it is apparently more politically comfortable to let people find out the hard way than to hand them a dollar’s worth of certainty first. The 48,465 strips Kentucky handed out this year are the counterfactual sitting right there in the paperwork — proof the tool was working, in the exact month someone decided it shouldn’t be funded anymore.